51. An economic evaluation of rosuvastatin treatment in systolic heart failure
- Author
-
Paula K, Lorgelly, Andrew H, Briggs, Hans, Wedel, Peter, Dunselman, Ake, Hjalmarson, John, Kjekshus, Finn, Waagstein, John, Wikstrand, András, Jánosi, Dirk J, van Veldhuisen, Vivencio, Barrios, Cândida, Fonseca, John J V, McMurray, Karl, Swedberg, Faculteit Medische Wetenschappen/UMCG, and Cardiovascular Centre (CVC)
- Subjects
Male ,medicine.medical_specialty ,Statin ,Cost effectiveness ,medicine.drug_class ,Cost-Benefit Analysis ,medicine.medical_treatment ,Heart failure ,ALONGSIDE ,law.invention ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,Rosuvastatin ,Hospital Mortality ,Prospective Studies ,Rosuvastatin Calcium ,Prospective cohort study ,health care economics and organizations ,Aged ,Heart transplantation ,Sulfonamides ,Cardiopulmonary Bypass ,business.industry ,Statins ,nutritional and metabolic diseases ,Multinational trial ,Middle Aged ,medicine.disease ,Surgery ,LIFETIME RISK ,Fluorobenzenes ,Hospitalization ,Pyrimidines ,Costs and Cost Analysis ,Cardiology ,Heart Transplantation ,Female ,Cost-effectiveness ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Cardiology and Cardiovascular Medicine ,business ,COSTS ,medicine.drug - Abstract
To estimate the cost-effectiveness of 10 mg rosuvastatin daily for older patients with systolic heart failure in the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial.This within trial analysis of CORONA used major cardiovascular (CV) events as the outcome measure. Resource use was valued and the costs of hospitalizations, procedures, and statin use compared. Cost-effectiveness was estimated as cost per major CV event avoided. There were significantly fewer major CV events in the rosuvastatin group compared with the placebo group (1.04 vs. 1.20 per patient; difference 0.164; 95% CI: 0.075-0.254, P This economic analysis showed that a significant reduction in major CV events with rosuvastatin led to significantly reduced costs of CV hospitalizations and procedures. The reduction in associated costs for major CV events was found to offset partially (by 44%) the cost of rosuvastatin treatment in patients with systolic heart failure.
- Published
- 2010
- Full Text
- View/download PDF